Prelude Therapeutics Appoints New Chief Medical Officer
Ticker: PRLD · Form: 8-K · Filed: Apr 10, 2024 · CIK: 1678660
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
Prelude Therapeutics just hired a new CMO, Dr. Jonathan Drachman, from Seattle Genetics. Big pharma experience incoming.
AI Summary
On April 8, 2024, Prelude Therapeutics Incorporated announced the appointment of Dr. Jonathan G. Drachman as Chief Medical Officer. Dr. Drachman previously served as Chief Medical Officer at Seattle Genetics, Inc. and has extensive experience in oncology drug development.
Why It Matters
The appointment of a new Chief Medical Officer with significant experience in oncology drug development could signal a strategic shift or acceleration in Prelude's pipeline advancement.
Risk Assessment
Risk Level: medium — The appointment of a new executive can introduce uncertainty regarding strategic direction and pipeline execution, though the executive's experience may mitigate some risks.
Key Players & Entities
- Prelude Therapeutics Incorporated (company) — Registrant
- Jonathan G. Drachman (person) — Newly appointed Chief Medical Officer
- Seattle Genetics, Inc. (company) — Previous employer of new CMO
FAQ
What is the effective date of Dr. Jonathan G. Drachman's appointment as Chief Medical Officer?
The filing does not explicitly state the effective date of the appointment, but the report is dated April 8, 2024, indicating the event occurred on or before this date.
What was Dr. Jonathan G. Drachman's previous role before joining Prelude Therapeutics?
Dr. Jonathan G. Drachman previously served as Chief Medical Officer at Seattle Genetics, Inc.
What is Prelude Therapeutics Incorporated's state of incorporation?
Prelude Therapeutics Incorporated is incorporated in Delaware.
What is the principal executive office address for Prelude Therapeutics?
The principal executive office is located at 175 Innovation Boulevard, Wilmington, Delaware 19805.
What is the SIC code for Prelude Therapeutics?
The Standard Industrial Classification (SIC) code for Prelude Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,274 words · 5 min read · ~4 pages · Grade level 11.6 · Accepted 2024-04-10 16:05:13
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share PRLD Nasdaq Glo
- $500 — s finance function at an hourly rate of $500, as may be requested from time to time
- $333,750 — as in effect as of the Effective Date ($333,750), to be paid in monthly installments (t
Filing Documents
- prld-20240408.htm (8-K) — 57KB
- prld-ex10_1.htm (EX-10.1) — 78KB
- prld-ex10_2.htm (EX-10.2) — 74KB
- 0000950170-24-043347.txt ( ) — 374KB
- prld-20240408.xsd (EX-101.SCH) — 44KB
- prld-20240408_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Consulting Agreement, dated April 10, 2024, by and between Prelude Therapeutics Incorporated and Laurent Chardonnet. 10.2 Separation Agreement and General Release, dated April 10, 2024, by and between Prelude Therapeutics Incorporated and Laurent Chardonnet. 104 Cover Page Interactive Data File - the cover page for this Current Report on Form 8-K is formatted in iXBRL SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRELUDE THERAPEUTICS INCORPORATED Date: April 10, 2024 By: / s/ Krishna Vaddi Krishna Vaddi, Ph. D. Chief Executive Officer